Illumina (Nasdaq:ILMN) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

ILMN Overzicht aandelen

Illumina, Inc. biedt sequentie- en arraygebaseerde oplossingen voor genetische en genomische analyse in de Verenigde Staten, Singapore, het Verenigd Koninkrijk en internationaal.

Over het bedrijf

ILMN fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	3/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Beloningen

De winst zal naar verwachting met 75.56% per jaar groeien

Risicoanalyse

Geen risico's gedetecteerd voor ILMN uit onze risicocontroles.

Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

WarrenAI

Based on Analyst Price Targets

NovaSeq X Series Expansion To Propel Growth Amid Global Economic Hurdles

US$149.23

5.2% undervalued

4.58%

Revenue growth p.a.

2 days ago

Illumina, Inc. Concurrenten

Waters

NYSE:WAT

US$21.0b

West Pharmaceutical Services

NYSE:WST

US$21.6b

Avantor

NYSE:AVTR

US$17.1b

Mettler-Toledo International

NYSE:MTD

US$31.1b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Illumina
Historische aandelenkoersen
Huidige aandelenkoers	US$141.43
52 Week Hoogtepunt	US$148.19
52 Week Laag	US$89.00
Bèta	1.15
11 maand verandering	9.99%
3 maanden verandering	30.33%
1 Jaar Verandering	1.01%
33 jaar verandering	-65.50%
5 jaar verandering	-53.26%
Verandering sinds IPO	622.10%

Recent nieuws en updates

Illumina Sees The Light: GRAIL Is Gone, Focus Restored (Rating Upgrade)

Aug 21

Recent updates

Illumina Sees The Light: GRAIL Is Gone, Focus Restored (Rating Upgrade)

Aug 21

Illumina: Strengthening Competitive Position, Relevance And A Very Compelling Valuation

Jul 23

Illumina, Inc.'s (NASDAQ:ILMN) Share Price Could Signal Some Risk

Jul 01

Illumina: Marriage Made In Hell Is (Finally) Over - Assessing Impact Of GRAIL Spin-Out

Jun 28

Investors Appear Satisfied With Illumina, Inc.'s (NASDAQ:ILMN) Prospects As Shares Rocket 40%

Dec 21

Is Illumina, Inc. (NASDAQ:ILMN) Potentially Undervalued?

Dec 03

Would Illumina (NASDAQ:ILMN) Be Better Off With Less Debt?

Oct 24

Is There An Opportunity With Illumina, Inc.'s (NASDAQ:ILMN) 40% Undervaluation?

Oct 03

At US$167, Is Illumina, Inc. (NASDAQ:ILMN) Worth Looking At Closely?

Aug 22

The Big Trends: New Frontiers in Healthcare

Jul 13

Estimating The Intrinsic Value Of Illumina, Inc. (NASDAQ:ILMN)

Jul 03

Illumina (NASDAQ:ILMN) Is Carrying A Fair Bit Of Debt

Jun 13

Is It Time To Consider Buying Illumina, Inc. (NASDAQ:ILMN)?

Apr 12

Is Illumina (NASDAQ:ILMN) Using Too Much Debt?

Mar 14

Are Investors Undervaluing Illumina, Inc. (NASDAQ:ILMN) By 38%?

Dec 30

Should You Investigate Illumina, Inc. (NASDAQ:ILMN) At US$221?

Dec 02

Rendement voor aandeelhouders

	ILMN	US Life Sciences	US Markt
7D	8.7%	-2.0%	0.3%
1Y	1.0%	15.2%	32.4%

Rendement versus industrie: ILMN presteerde slechter dan de US Life Sciences -sector, die het afgelopen jaar een rendement van 17.6 % opleverde.

Rendement versus markt: ILMN presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 34.1 % opleverde.

Prijsvolatiliteit

Is ILMN's price volatile compared to industry and market?
ILMN volatility
ILMN Average Weekly Movement	6.1%
Life Sciences Industry Average Movement	8.7%
Market Average Movement	6.4%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: ILMN heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 6% ) van ILMN is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1998	10,615	Jacob Thaysen	www.illumina.com

Illumina, Inc. biedt sequencing- en array-gebaseerde oplossingen voor genetische en genomische analyse in de Verenigde Staten, Singapore, het Verenigd Koninkrijk en internationaal. Het bedrijf is actief via de segmenten Core Illumina en GRAIL. Het bedrijf biedt sequencing- en arraygebaseerde instrumenten en verbruiksartikelen, waaronder reagentia, flowcellen en bibliotheekpreparaten; genoomsequencingkits, waarmee volledige genomen van verschillende grootte en complexiteit worden gesequencet; en gerichte resequencingkits, waarmee exomen, specifieke genen en RNA of andere interessante genoomregio's worden gesequencet.

Illumina, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Illumina zich tot de beurswaarde?
ILMN fundamentele statistieken
Marktkapitalisatie	US$21.72b
Inkomsten(TTM)	-US$3.04b
Inkomsten(TTM)	US$4.43b

5.1x

P/S-verhouding

-7.4x

Koers/Winstverhouding

Is ILMN overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
ILMN resultatenrekening (TTM)
Inkomsten	US$4.43b
Kosten van inkomsten	US$1.49b
Brutowinst	US$2.94b
Overige uitgaven	US$5.98b
Inkomsten	-US$3.04b

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-19.11
Brutomarge	66.34%
Nettowinstmarge	-68.73%
Schuld/Eigen Vermogen Verhouding	155.6%

Hoe presteerde ILMN op de lange termijn?

Bekijk historische prestaties en vergelijking

ILMN Overzicht aandelen

Beloningen

Risicoanalyse

NovaSeq X Series Expansion To Propel Growth Amid Global Economic Hurdles

Illumina, Inc. Concurrenten

NYSE:WAT

US$21.0b

NYSE:WST

US$21.6b

NYSE:AVTR

US$17.1b

NYSE:MTD

US$31.1b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Illumina, Inc. Announces Executive Changes

European Court of Justice Rules in Favor of Illumina, Inc. in Relation to Relation to the European Commission's Acquisition of GRAIL

Illumina, Inc. Announces Food and Drug Administration Approval for Its Cancer Biomarker Test with Two Companion Diagnostics to Rapidly Match Patients to Targeted Therapies

Illumina Sees The Light: GRAIL Is Gone, Focus Restored (Rating Upgrade)

Consensus EPS estimates upgraded to US$9.60 loss

Now 23% overvalued after recent price rise

Recent updates

Illumina, Inc. Announces Executive Changes

European Court of Justice Rules in Favor of Illumina, Inc. in Relation to Relation to the European Commission's Acquisition of GRAIL

Illumina, Inc. Announces Food and Drug Administration Approval for Its Cancer Biomarker Test with Two Companion Diagnostics to Rapidly Match Patients to Targeted Therapies

Illumina Sees The Light: GRAIL Is Gone, Focus Restored (Rating Upgrade)

Consensus EPS estimates upgraded to US$9.60 loss

Now 23% overvalued after recent price rise

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Illumina, Inc. Announces Impairment Charges for the Second Quarter Ended June 30, 2024

Illumina Launches New Oncology Menu for NovaSeq X Series Customers

Consensus EPS estimates fall from profit to US$1.71 loss

Illumina: Strengthening Competitive Position, Relevance And A Very Compelling Valuation

Illumina, Inc. (NasdaqGS:ILMN) acquired Fluent BioSciences Inc.

Illumina, Inc. (NasdaqGS:ILMN) acquired Fluent BioSciences Inc.

Illumina, Inc.'s (NASDAQ:ILMN) Share Price Could Signal Some Risk

Illumina: Marriage Made In Hell Is (Finally) Over - Assessing Impact Of GRAIL Spin-Out

Consensus EPS estimates upgraded to US$0.93 loss

Illumina, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Illumina, Inc.(NasdaqGS:ILMN) dropped from S&P 500 Value

Now 24% overvalued

Illumina Launches Latest Chemistry Across Most Popular Mid-Throughput Sequencers, Enabling Higher Quality and Greater Speed for Customers at Lower Cost

Should You Investigate Illumina, Inc. (NASDAQ:ILMN) At US$106?

Illumina, Inc. Appoints Anna Richo to its Board of Directors

Now 22% overvalued

Illumina: Expect A Slow Rebound

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Illumina, Inc. Reaffirms Earnings Guidance for the Fiscal Year 2024

Calculating The Fair Value Of Illumina, Inc. (NASDAQ:ILMN)

Consensus EPS estimates fall by 25%

Illumina, Inc. Announces Chief Financial Officer Changes

Illumina, Inc. to Report Q1, 2024 Results on May 02, 2024

Consensus EPS estimates upgraded to US$0.56 loss

Revenues Not Telling The Story For Illumina, Inc. (NASDAQ:ILMN)

CEO & Director recently bought US$992k worth of stock

Illumina: Stagnant Revenues And Shrinking Margins Amidst Rising Competition

Consensus EPS estimates fall by 64%

Consensus EPS estimates upgraded to US$0.41 loss, revenue downgraded

Full year 2023 earnings: EPS misses analyst expectations

Illumina, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Would Illumina (NASDAQ:ILMN) Be Better Off With Less Debt?

Illumina: Volatility Galore, But Not Much Prospect Of Progress In 2024

Illumina, Inc. to Report Q4, 2023 Results on Feb 08, 2024

Pomerantz LLP Files a Class Action Lawsuit Against Illumina, Inc

Investors Appear Satisfied With Illumina, Inc.'s (NASDAQ:ILMN) Prospects As Shares Rocket 40%

Carl C. Icahn Releases Open Letter to Stockholders of Illumina, Inc

Now 20% undervalued after recent price drop

Hagens Berman Encourages Illumina Investors with Losses to Contact Firm’s Attorneys

Is Illumina, Inc. (NASDAQ:ILMN) Potentially Undervalued?

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Illumina, Inc

Price target decreased by 15% to US$168

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Carl Icahn Accuses Board and Ex-CEO of Illumina Inc

Would Illumina (NASDAQ:ILMN) Be Better Off With Less Debt?

Carl Icahn Sues Illumina Inc’s Board for Violating Fiduciary Duties

Price target decreased by 9.4% to US$203

EU Orders Illumina to Sell Cancer Testing Firm Grail

Illumina, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Is There An Opportunity With Illumina, Inc.'s (NASDAQ:ILMN) 40% Undervaluation?

Illumina, Ventures Announces Appointment of Mara Aspinall, MBA as Partner of Investment Team